WOBURN, Mass. , Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be held September 11 - 13.  PAINWeek is the preferred resource in the U.S.

WOBURN, Mass. , Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of diabetic peripheral neuropathy (DPN).  DPNCheck is a widely used point-of-care test that provides

WOBURN, Mass. , Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH -funded, multi-site randomized controlled trial (RCT) of the efficacy of transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced

WOBURN, Mass. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) published an infographic on chronic knee pain ( available here ) and provided an update on how Quell technology addresses knee pain. One-quarter of U.S. adults suffer from frequent knee pain, which decreases

WOBURN, Mass. , July 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020 . The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health

WOBURN, Mass. , July 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the market on Thursday, July 23, 2020 . The Company will host a conference call at 8:00 a.m., Eastern Time on July

WOBURN, Mass. , July 09, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduction test for evaluation of peripheral neuropathies such as diabetic peripheral neuropathy (DPN).

WOBURN, Mass. , June 25, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral neuropathy detection within Medicare Advantage and other value-based care markets.

WOBURN, Mass. , June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain.  This effort includes direct-to-consumer digital marketing as well as informing physicians and other health care providers

WOBURN, Mass. , April 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2020 .  The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic